Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease

The diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms of dementia with similar clinical pictures, than the diagnostic accuracy of AD is low. Improved methods of early diagnosis are needed, particularly because drugs treatment is more effective in the early stages of the disease. Recent research focused the attention to biochemical diagnostic markers (biomarkers) and according to the proposal of a consensus group on biomarkers, three candidate CSF markers reflecting the pathological AD processes, have recently been identified: total tau protein (t‐tau), amyloid ß(1–42) protein (Aß42), and tau protein phosphorylated at AD‐specific epitopes (p‐tau). Several articles report reduced CSF levels of Aß42 and increased CSF levels of t‐tau and p‐tau in AD; the sensitivity and specificity of these data are able for discrimination of AD patients from controls. However, the specificity for other dementias is low. According to the literature analysis reported in the present review, we can conclude that the combination of the CSF markers and their ratios may significantly increase the specificity and the accuracy of AD diagnosis. © 2006 Wiley‐Liss, Inc.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  D. Selkoe,et al.  Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Fishman.  Cerebrospinal Fluid in Diseases of the Nervous System , 1992 .

[4]  D. Selkoe,et al.  Normal Cellular Processing of the β‐Amyloid Precursor Protein Results in the Secretion of the Amyloid β Peptide and Related Molecules a , 1993 .

[5]  D. Selkoe,et al.  Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. , 1993, Annals of the New York Academy of Sciences.

[6]  Jan Six,et al.  Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay , 1993 .

[7]  M. Goedert.  Tau protein and the neurofibrillary pathology of Alzheimer's disease , 1993, Trends in Neurosciences.

[8]  S. Harik.  Cerebrospinal Fluid in Diseases of the Nervous System, 2nd Ed. , 1994, Neurology.

[9]  L A Hansen,et al.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias. , 1994, Archives of neurology.

[10]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[11]  G. Drewes,et al.  Tau domains, phosphorylation, and interactions with microtubules , 1995, Neurobiology of Aging.

[12]  L. Chang,et al.  Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease , 1995, Neurology.

[13]  J. Trojanowski,et al.  Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.

[14]  R. Maccioni,et al.  Role of microtubule-associated proteins in the control of microtubule assembly. , 1995, Physiological reviews.

[15]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[16]  C. Hock,et al.  Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment , 1995, Annals of neurology.

[17]  Lars Lannfelt,et al.  Increased cerebrospinal fluid tau in patients with Alzheimer's disease , 1995, Neuroscience Letters.

[18]  K. Jellinger,et al.  Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[19]  D. Selkoe,et al.  Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Kurz,et al.  Cerebrospinal protein tau is elevated in early Alzheimer's disease , 1996, Neuroscience Letters.

[21]  H. Arai,et al.  Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. , 1997, Gerontology.

[22]  D. Galasko,et al.  Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease , 1997, Neurology.

[23]  J. Kornhuber,et al.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.

[24]  K. Blennow,et al.  Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF , 1998 .

[25]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[26]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[27]  H. Soininen,et al.  CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease , 1998, Neurology.

[28]  T. Kudo,et al.  Increased tau protein level in postmortem cerebrospinal fluid , 1998, Psychiatry and clinical neurosciences.

[29]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[30]  A. Kurz,et al.  Tau Protein in Cerebrospinal Fluid Is Significantly Increased at the Earliest Clinical Stage of Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[31]  S. Hirai,et al.  Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. , 1998, Journal of the neurological sciences.

[32]  M. Goedert,et al.  Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.

[33]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. , 1998, Annals of neurology.

[34]  H. Arai,et al.  No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia , 1998, Neuroscience Letters.

[35]  Khadija Iqbal,et al.  Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. , 1998, Journal of neural transmission. Supplementum.

[36]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[37]  P. Mecocci,et al.  Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? , 1998, Alzheimer disease and associated disorders.

[38]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[39]  Y. Nakamura,et al.  Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. , 1998, Methods and findings in experimental and clinical pharmacology.

[40]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[41]  Hiroyuki Arai,et al.  Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease , 1999, Neuroscience Letters.

[42]  C. Guaza,et al.  Increased cerebrospinal fluid cAMP levels in Alzheimer's disease , 1999, Brain Research.

[43]  K. Nakashima,et al.  A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy , 1999, Neuroscience Letters.

[44]  S. Rapoport,et al.  Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls , 1999, Neuroscience Letters.

[45]  R. Maccioni,et al.  Inhibition of tau phosphorylating protein kinase cdk5 prevents β‐amyloid‐induced neuronal death , 1999, FEBS letters.

[46]  H. Arai,et al.  Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. , 1999, Alcoholism, clinical and experimental research.

[47]  R. Rudick,et al.  Quantification of Axonal Damage in Traumatic Brain Injury , 1999, Journal of neurochemistry.

[48]  P. Vermersch,et al.  Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. , 1999, Neuroreport.

[49]  K. Blennow,et al.  Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.

[50]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[51]  M. Rossor,et al.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.

[52]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[53]  H. Hampel,et al.  Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients , 2000, Neuroscience Letters.

[54]  M. Neumann,et al.  Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.

[55]  K. Blennow,et al.  Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD , 2000, Neurology.

[56]  K. Blennow,et al.  CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.

[57]  K. Blennow,et al.  Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. , 2000, Journal of Alzheimer's disease : JAD.

[58]  J. Kornhuber,et al.  Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease , 2000, Neurology.

[59]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. , 2000, Neuroscience letters.

[60]  Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. , 2000 .

[61]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[62]  Nobuyuki Okamura,et al.  CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study , 2000, Experimental Neurology.

[63]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[64]  K. Blennow,et al.  Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment , 2001, Neuroscience Letters.

[65]  J. Wiltfang,et al.  Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.

[66]  L. Parnetti,et al.  CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies , 2001, Neurological Sciences.

[67]  L. Barbeito,et al.  The molecular bases of Alzheimer's disease and other neurodegenerative disorders. , 2001, Archives of medical research.

[68]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[69]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[70]  K. Blennow,et al.  Both total and phosphorylated tau are increased in Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[71]  L. Boylan,et al.  Developmental apraxia arising from neonatal brachial plexus palsy , 2001, Neurology.

[72]  M. Michalopoulou,et al.  Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[73]  H. Arai,et al.  Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease , 2001, Experimental Neurology.

[74]  Katharina Buerger,et al.  Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.

[75]  A Drzezga,et al.  Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration , 2002, Neurology.

[76]  Katharina Buerger,et al.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.

[77]  I. Grundke‐Iqbal,et al.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. , 2002, The American journal of pathology.

[78]  A. Cagnin,et al.  Combined analysis of CSF βA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data , 2002, Journal of neural transmission.

[79]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[80]  E. Mandelkow,et al.  Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress , 2002, The Journal of cell biology.

[81]  P. Scheltens,et al.  CSF markers related to pathogenetic mechanisms in Alzheimer's disease , 2002, Journal of Neural Transmission.

[82]  K. Blennow,et al.  Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia , 2002, Dementia and Geriatric Cognitive Disorders.

[83]  J. Blass.  Cerebrometabolic abnormalities in Alzheimer's disease , 2003, Neurological research.

[84]  H. Ulmer,et al.  Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury , 2003, Neurology.

[85]  R. Nitsch,et al.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. , 2003, Archives of neurology.

[86]  Trey Sunderland,et al.  Decreased-Amyloid 1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease , 2003 .

[87]  Li-Huei Tsai,et al.  Aberrant Cdk5 Activation by p25 Triggers Pathological Events Leading to Neurodegeneration and Neurofibrillary Tangles , 2003, Neuron.

[88]  Philip Scheltens,et al.  Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration , 2003, Neurology.

[89]  T. del Ser,et al.  Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. , 2003, Archives of neurology.

[90]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[91]  P. Scheltens,et al.  Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. , 2003, Archives of neurology.

[92]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[93]  F. Bolgert,et al.  Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. , 2003, Archives of neurology.

[94]  J. Leszek,et al.  Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[95]  G. Hart,et al.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[97]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[98]  I. Grundke‐Iqbal,et al.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5 , 1997, Molecular and Cellular Biochemistry.

[99]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[100]  Hilkka Soininen,et al.  CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment , 2005, Neurology.

[101]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[102]  M. Husain,et al.  Clinical diagnosis and management of Alzheimer's disease. , 2005, Neuroimaging clinics of North America.

[103]  G. Bernardi,et al.  AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis , 2005, Journal of the Neurological Sciences.

[104]  K. Blennow,et al.  CSF biomarkers for mild cognitive impairment and early Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.

[105]  A. Ivanoiu,et al.  Cerebrospinal fluid TAU protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer’s disease and correlation with the neuropsychological examination , 2005, Neurocase.

[106]  P. Spano,et al.  Ethanol metabolism and striatal dopamine turnover , 2005, Journal of Neural Transmission.

[107]  Jeffrey L. Cummings,et al.  Definitions and diagnostic criteria , 2006 .

[108]  Harald Hampel,et al.  CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease , 2001, Molecular Neurobiology.